Cimzia UK Access Scheme Reinforces Marketing Message
Executive Summary
It seems that UK cost-sharing schemes - agreements whereby drug companies offer the National Health Service rebates or free doses of their medicines - aren't just about winning a favorable reimbursement policy. They can help further the product's marketing message too
You may also be interested in...
NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
Cancer drug is effective but still too expensive even with a 7 percent price cut, NICE concludes.
UCB Bets on Focus, Not Diversification
In contrast to some Big Pharmas, mid-sized UCB has shifted from a diversified to a very focused business model. That means it's relying heavily on commercial success for its three newest drugs. If the new products take off, UCB could by 2012 be delivering stronger earnings growth than its more diversified peers, just as some of them begin to face the worst of their patent cliffs. But it has little room to maneuver if even one of these disappoints.
UCB Bets on Focus, Not Diversification
In contrast to some Big Pharmas, mid-sized UCB has shifted from a diversified to a very focused business model. That means it's relying heavily on commercial success for its three newest drugs. If the new products take off, UCB could by 2012 be delivering stronger earnings growth than its more diversified peers, just as some of them begin to face the worst of their patent cliffs. But it has little room to maneuver if even one of these disappoints.